RZLT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Not a good buy right now. RZLT is trading around $3.30 despite major recent clinical-trial disappointment and a wave of price-target cuts; the most recent Wedbush target is $2 (Neutral), which is still below the current price. With no Intellectia buy signals, negative news flow (investigation headlines), high volatility, and an upcoming earnings event (2026-02-12) that could reprice the stock quickly, the risk/reward is unfavorable for an impatient buyer.
Price/Trend: Near-term stabilization but not a clean uptrend. MACD histogram is positive (0.238) yet contracting, implying bullish momentum is fading rather than accelerating. RSI(6)=58.36 is neutral-to-slightly-bullish but not an overbought/oversold signal. Moving averages: Converging MAs suggest indecision and potential range trading rather than a strong trend. Levels: Pivot 3.188 is the key near-term line; holding above it is constructive. Resistance sits at R1 3.554 then R2 3.781; the stock likely needs to reclaim/hold above ~3.55 to look like a higher-probability breakout. Downside support is S1 2.821 then S2 2.594; a break below ~2.82 would likely invite another leg down. Intellectia Proprietary Trading Signals:
Potential FDA/strategy pathway discussions could reframe the program if management presents a credible post-hoc analysis and a viable regulatory plan.
Technical: Price is above pivot (3.188), and the MACD remains positive (still modestly supportive if it re-expands).
Some Street analysts still rate Buy (e.g., Guggenheim/Maxim/H.C. Wainwright) despite reduced targets, implying perceived optionality if the pipeline path improves.
Possible short-term bounce dynamics given high volatility and heavy call open interest.
keep sentiment negative.
Latest quarter: 2026/Q1. Revenue was $0 (no YoY growth). Net income improved to -$18.15M (loss narrowed ~18.0% YoY), but EPS worsened to -$0.18 (down ~18.18% YoY). Overall: still pre-revenue and loss-making; the modest loss improvement doesn’t offset the pipeline/trial-driven uncertainty that dominates valuation and near-term trading.
Recent trend: Broadly negative reset in December 2025 after the Phase 3 failure—multiple firms slashed targets dramatically (e.g., Wedbush $12→$1 with a downgrade; Guggenheim $15→$6; Maxim $20→$4; H.C. Wainwright $14→$5) and Cantor downgraded to Neutral. Most recent notable change (2026-01-08) was Wedbush raising its PT modestly to $2 from $1 but still keeping Neutral and explicitly questioning whether the benefit magnitude is enough for approval. Wall Street pros/cons view: Pros—pipeline optionality and a theoretical path forward if regulatory strategy becomes credible; some Buy ratings remain. Cons—trial failure drives uncertainty around approvability and timelines, leading to reduced probability-of-success assumptions and targets that, in key cases, sit below the current share price. Net: Street tone remains cautious/negative despite pockets of optimism.
